NCT00961363UnknownPhase 2
The Effect of Sitagliptin on Postprandial Glycemia and Endothelial Function in Chinese Subjects With Impaired Glucose Tolerance
National Taiwan University Hospital1 site in 1 country60 target enrollmentStarted: December 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- the change in fasting and post-load plasma glucose levels during OGTT
Study Overview
Brief Summary
The purpose of this study is to examine the safety and efficacy of sitagliptin 100 mg every day (q.d.) in improving hyperglycemia and endothelial dysfunction in subjects with impaired glucose tolerance.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 40 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Chinese subjects aged 40-65 years with fasting plasma glucose < 100 mg/dL and OGTT 2-hour glucose 140-199 mg/dL.
- •Subjects are judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests.
- •Subject has an understanding of the study procedures, alternative treatments available and risk involved with the study, and voluntarily agrees to participate by giving written informed consent.
- •Non-sterilized premenopausal female agrees to receive pregnancy test to confirm the non-pregnancy status and use adequate contraceptive methods to prevent pregnancy during the study period. Patient status should be confirmed by pregnancy test before enrollment.
Exclusion Criteria
- •Evidence of diabetes (FPG> 125 mg/dL, or OGTT 2-hour glucose>=200 mg/dL, or current use of an anti-diabetic agents, except for history of gestational diabetes).
- •History of intolerance or hypersensitivity or contraindication as mentioned in the approved package insert (appendix).
- •Patient has any of the following disorders within the past 6 months: acute coronary syndrome (e.g., MI or unstable angina), coronary artery intervention (e.g., CABG or PTCA), stroke or transient ischemic neurological disorder.
- •Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months.
- •Patient has a BMI > 40 kg/m
- •Patient is on or likely to require more than 14 consecutive days or repeated courses of pharmacologic doses of corticosteroids. Note: inhaled, nasal, and topical corticosteroids are permitted.
- •Patient is on or likely to require treatment with immunosuppressive agents (e.g., cyclosporine, methotrexate).
- •Advanced renal insufficiency (estimated creatinine clearance < 50 ml/min).
- •Severe hepatic insufficiency (Child-Pugh score > 9, see Appendix).
Arms & Interventions
Sitagliptin
Experimental
Sitagliptin
Intervention: Sitagliptin (Drug)
Placebo
Placebo Comparator
Placebo
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
the change in fasting and post-load plasma glucose levels during OGTT
Time Frame: 24 weeks
Secondary Outcomes
- the changes in endothelial function, measured by circulating adhesion molecules(24 weeks)
- the changes in beta cell functions derived from the glucose/insulin levels during OGTT(24 weeks)
- the safety and the tolerability of sitagliptin, including clinical and laboratory adverse experiences, laboratory values, weight, and vital signs.(24 weeks)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 DiabetesDiabetes MellitusGastroparesisNCT02324010Royal Adelaide Hospital14
Withdrawn
Not Applicable
Sitagliptin in Type I Diabetic PatientsDiabetes Type INCT01741103University at Buffalo
Completed
Not Applicable
Sitagliptin Use and its Continuous Glycemic Control Effcets in Japanese patients with type 2 diabetes in SaitamaType 2 diabetesJPRN-UMIN000005076Dokkyo Medical University,Koshigaya Hospital50
Completed
Not Applicable
Comparison of the effects of sitagliptin and mitiglinide/voglibose fixed-dose combination tablets on glucose metabolism in patients with uncontrolled type-2 diabetes mellitus.JPRN-UMIN000008274niversity of Occupational and Environmental Health, Japan5
Completed
Not Applicable
Study on the effects of sitagliptin on glycemic control in newly treated or uncontrolled patients with type 2 diabetes mellitusType 2 diabetes mellitusJPRN-UMIN000019154Kanto Antidiabetics Study Group1,400